Results 91 to 100 of about 10,517,468 (269)

Long‐term outcomes of haploidentical hematopoietic stem cell transplantation with antithymocyte globulin–based myeloablative conditioning in pediatric refractory or relapsed non‐Hodgkin lymphoma

Pediatric Investigation, EarlyView.
Single‐center retrospective data showed that ATG‐based myeloablative haploidentical hematopoietic stem cell transplantation provides durable remission and favorable long‐term survival in children with refractory/relapsed non‐Hodgkin lymphoma, achieving high engraftment rates, low relapse incidence, and acceptable toxicity.
Chenguang Jia, Jie Zheng, Meng Yuan, Hongbo He, Yibo Fan, Bin Wang, Guanghua Zhu, Jun Yang, Yanhui Luo, Lixiao Cai, Pan Zhang, Yanlong Duan, Maoquan Qin   +12 more
wiley   +1 more source

T-Cell Lymphoblastic Lymphoma with Cutaneous Involvement in a Child: A Rare Case Report

Clinical, Cosmetic and Investigational Dermatology, 2022
Jiaoquan Chen,* Xin Tian,* Nanji Yu, Liqian Peng, Huilan Zhu Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, 510095, People’s Republic of China*These authors contributed equally to this workCorrespondence: Huilan Zhu,
Chen J, Tian X, Yu N, Peng L, Zhu H
doaj  

Bortezomib‐based chemotherapy in Chinese pediatric patients with relapsed/refractory acute lymphoblastic leukemia: A single‐center retrospective study

Pediatric Investigation, EarlyView.
Bortezomib‐based chemotherapy achieved an 88.9% remission rate in Chinese pediatric patients with relapsed/refractory B‐cell acute lymphoblastic leukemia, enabling 62.5% of responders to bridge to transplantation, while T‐cell acute lymphoblastic leukemia showed no response.
Xingyu Zhao, Jian Wang, Liping Que, Dunhua Zhou, Jianpei Fang, Luhong Xu   +5 more
wiley   +1 more source

Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004

Haematologica, 2006
We report a population-based investigation on adult acute precursor B lymphoblastic leukemia, Burkitt's lymphoma and T lymphoblastic lymphoma in a defined geographic area.
J Lamvik, A Waage, SG Wahl, I Naess, PQ Paulsen, J Hammerstrom   +5 more
doaj  

Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma

Blood, 2005
AbstractChromosomal rearrangements affecting RUNX1 and CBFB are common in acute leukemias. These mutations result in the expression of fusion proteins that act dominant-negatively to suppress the normal function of the Runt-related transcription factor 1 (RUNX)/core binding factor β (CBFβ) complexes.
Mondira, Kundu, Sheila, Compton, Lisa, Garrett-Beal, Terryl, Stacy, Matthew F, Starost, Michael, Eckhaus, Nancy A, Speck, P Paul, Liu   +7 more
openaire   +3 more sources

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

, 2014
Peripheral T-cell lymphoma (PTCL) encompasses a heterogeneous group of neoplasms with generally poor clinical outcome. Currently 50% of PTCL cases are not classifiable: PTCL-not otherwise specified (NOS).
Connors, J.M., Wilcox, R.A., Staudt, L.M., Rimsza, L.M., Rosenwald, A., Smith, L., the International Peripheral T-cell Lymphoma, Project, Gascoyne, R.D., Iqbal, J., Braziel, R.M., Lim, S.T., Au, W.Y., Wang, C., Geissinger, E., Gaulard, P., Tan, S.Y., Nakamura, S., Vose, J., Seto, M., Weisenburger, D.D., Delabie, J., Lymphoma Leukemia Molecular Profiling, Project, Jaffe, E.S., Cook, J.R., Guo, S., Armitage, J., Martinez, A., Berger, F., Chan, W.C., Greiner, T.C., Tubbs, R.R., Campo, E., Pileri, S.A., Wright, G., Teh, B.T., Ott, G., Piccaluga, P.P., de Leval, L.   +37 more
core   +1 more source

Combination of artesunate and ruxolitinib suppresses T cell leukemia/lymphoma proliferation via the JAK STAT pathway

Scientific Reports
T-cell lymphoblastic leukemia/lymphoma is a highly aggressive malignancy with a 5-year overall survival rate of 35%. Mutations in the JAK/STAT pathway are the second most common mutations in T-cell lymphoblastic leukemia/lymphoma, and hyperactivation of ...
Yupei Yuan, Yan Li, Jie Li, Shuyu Wang, Fuyi Luo, Chen Huang, Jie Yang, Yujing Hu, Youchao Jia, Suyun Wang   +9 more
doaj   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source